FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone415-978-1200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$125.67 million
Profitability
Miscellaneous
Employees423
OptionableOptionable
FibroGen (NASDAQ:FGEN) Frequently Asked Questions
What is FibroGen's stock symbol?
FibroGen trades on the NASDAQ under the ticker symbol "FGEN."
How were FibroGen's earnings last quarter?
FibroGen Inc (NASDAQ:FGEN) issued its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.15. The biopharmaceutical company earned $29 million during the quarter, compared to analysts' expectations of $36.48 million. FibroGen had a negative return on equity of 24.59% and a negative net margin of 87.84%. The company's revenue for the quarter was down 28.6% compared to the same quarter last year. View FibroGen's Earnings History.
When is FibroGen's next earnings date?
What price target have analysts set for FGEN?
3 equities research analysts have issued 1 year price objectives for FibroGen's shares. Their forecasts range from $71.00 to $84.00. On average, they expect FibroGen's stock price to reach $76.3333 in the next year. This suggests a possible upside of 50.3% from the stock's current price. View Analyst Price Targets for FibroGen.
What is the consensus analysts' recommendation for FibroGen?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for FibroGen.
What are Wall Street analysts saying about FibroGen stock?
Here are some recent quotes from research analysts about FibroGen stock:
- 1. According to Zacks Investment Research, "FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California. " (1/9/2019)
- 2. Mizuho analysts commented, "We believe efficacy data is likely to be a non-event in 4Q18. But we believe MACE will be share-moving. We believe roxadustat can achieve superiority vs. epoetin alfa in the DD patient population, given encouraging mortality rate observed in recent studies vs. much higher historical rates with epoetin alfa. In NDD, we believe the bar is higher (comparing to placebo) but showing non-inferiority is possible (more below)." (12/17/2018)
Has FibroGen been receiving favorable news coverage?
News articles about FGEN stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. FibroGen earned a news impact score of -2.8 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an impact on the company's share price in the next few days.
Who are some of FibroGen's key competitors?
Some companies that are related to FibroGen include Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE) and Perrigo (PRGO).
Who are FibroGen's key executives?
FibroGen's management team includes the folowing people:
- Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 65)
- Mr. Pat Cotroneo, Chief Financial Officer (Age 55)
- Dr. K. Peony Yu, Chief Medical Officer (Age 57)
- Mr. Julian N. Stern, Sec. (Age 94)
- Dr. Barry A. Berkowitz, Founder
When did FibroGen IPO?
(FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.
Who are FibroGen's major shareholders?
FibroGen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Boston Advisors LLC (0.02%), Beacon Financial Group (0.01%) and Meeder Asset Management Inc. (0.00%). Company insiders that own FibroGen stock include Gerald Lema, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.
Which institutional investors are buying FibroGen stock?
How do I buy shares of FibroGen?
Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is FibroGen's stock price today?
One share of FGEN stock can currently be purchased for approximately $50.79.
How big of a company is FibroGen?
FibroGen has a market capitalization of $4.17 billion and generates $125.67 million in revenue each year. The biopharmaceutical company earns $-126,200,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. FibroGen employs 423 workers across the globe.
What is FibroGen's official website?
How can I contact FibroGen?
FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]
MarketBeat Community Rating for FibroGen (NASDAQ FGEN)
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
